文献速递白血病造血干细胞移植与细胞治疗

儿童B-ALL接受CAR-T后HLH样综合征与死亡及CD19阴性复发风险增加相关

HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL.
PubMed 文献 · Blood Adv · 2026-01-01

这项多中心回顾性研究分析了2018至2023年接受tisagenlecleucel治疗的154例儿童及年轻B-ALL患者,发现14.9%符合IEC-HS标准、21.4%符合HLH-LT标准,各定义间存在部分重叠。任何HLH样综合征均与较短的总生存和无事件生存相关,并独立预测CD19阴性复发(HR 8.10)。

要点

  • 接受tisagenlecleucel的儿童B-ALL中14.9%符合IEC-HS、21.4%符合HLH-LT标准。
  • HLH样综合征与1年非缓解/复发率60%及非复发死亡率11.4%相关。
  • 校正疾病负荷后,HLH样综合征独立预测CD19阴性复发(HR 8.10)。

核心结论

  • HLH样综合征各定义间存在部分重叠,IEC-HS具有预后意义,CD19阴性复发和非复发死亡是關鍵结局驱动因素。

研究设计与样本

  • 多中心回顾性研究,纳入2018至2023年接受tisagenlecleucel治疗的154例儿童和年轻B-ALL患者。

主要发现

  • 14.9%符合IEC-HS标准,21.4%符合HLH-LT标准,13%被治疗机构在电子健康记录中识别为HLH,10%符合所有定义。
  • 任何HLH样综合征与较短的总生存和无事件生存相关,校正基线疾病负荷后P< .0001。
  • 有HLH样综合征者1年非缓解/复发累积发生率为60%(95%CI 43.1-76.9),无者为28.2%(95%CI 20.0-36.5),P< .001。
  • 有HLH样综合征者1年非复发死亡累积发生率为11.4%(95%CI 0.7-22.1),无者为0%(95%CI 0-0),P< .001。
  • 高疾病负荷患者中,有HLH样综合征者1年CD19阴性复发累积发生率为65.2%(95%CI 44.7-85.8),无者为2%(95%CI 0-6.4),P< .001。

临床怎么用

  • 应关注CAR-T后HLH样综合征(包括IEC-HS和HLH-LT)的发生,因其与不良长期结局相关。
  • 对发生HLH样综合征的患者需警惕CD19阴性复发和非复发死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)-like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell-associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19- relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19- relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19- relapse and nonrelapse mortality as key outcome drivers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. McNerney KO, Kwon S, Naik S, et al. HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL. Blood Adv. 2026. PMID: 42469167. doi:10.1182/bloodadvances.2026020511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。